Apitolisib

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NameApitolisib
Drug Alias Name阿哌利塞apitolisibum阿托利司GDC-0980.1G-038390.1 +[9] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPI3-kinase class I inhibitorsmTOR Complex 2 inhibitorsMammalian target of Rapamycin (mTORC1) inhibitors
TargetsMammalian target of Rapamycin (mTORC1)mTOR Complex 2PI3-kinase class I
Therapy Area/IndicationsSolid tumoursProstatic NeoplasmsEndometrial Neoplasms +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[26] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesGenentech Inc
China Registration ClassN/A

Develop Information

Active CompaniesGenentech Inc
Inactive CompaniesN/A
Active IndicationsProstatic Neoplasms
Inactive IndicationsSolid tumoursEndometrial NeoplasmsBreast Neoplasms +[5] 

Other Information

ATC CodeN/A
Related LinksKEGG